Watchdogs want FDA number in DTC ads

Share this article:
Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.

The nonprofit presented the agency with a petition to that effect including 56,000 signatures. Consumer Reports, a publication of the group, released the results of a poll finding that of all respondents who had ever taken a prescription drug, 16% had experienced a serious side effect, but only 35% of all respondents were aware that side effects could be reported to FDA. 

Four out of five respondents reported seeing or hearing a drug ad within the past 30 days – nearly all on TV. Asked if ads should include reporting information, 87% said TV spots should, and 90% said print ads should do the same. 

A requirement that print ads – but not TV ads – include reporting info was included in last year's FDA Amendments Act, the group noted. Congress ordered a study on the feasibility of such a condition for TV ads as well, but the study, due at the end of March, has not been completed. 

“You can't turn on a TV today without seeing a drug ad, but those ads never mention that consumers should be reporting serious drug side effects to the FDA,” said Consumers Union campaign coordinator Liz Foley in a statement. “What better way for the FDA to let consumers know how to report serious problems with their medications than putting a toll-free number and website in all those drug ads we're bombarded by each day?”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...